FGFR1 Alteration clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
Our lead scientists for FGFR1 Alteration research studies include Saeed Sadeghi.